The Turing Pharmaceutical acquisition of Turing is finally coming to fruition, according to Reuters.
The deal will see the company purchase an 11 percent stake in Turing’s clinical trial arm, the company said in a press release.
The company will invest $10 million of the combined $10.5 billion, and it will use the funds to buy the drugmaker’s intellectual property and research capabilities.
Turing’s intellectual-property portfolio will include the following drugs: Pyrimethamine (Zyban): The first of the three approved drugs to treat the AIDS-associated chronic myelogenous leukemia (CML) that affects nearly one in five adults in the United States, PyrimetHAMINE (ZYB) is the most effective and most promising treatment option for this highly treatable disease.
Ebuprofen (Bupropion): This powerful painkiller is also the only FDA-approved opioid to be used to treat pain and chronic inflammation.
Zanamivir (Zanadig): This highly effective treatment is also approved for chronic pain and pain disorders.
Luminalis (Lumex): This drug is the first to be approved by the FDA for the treatment of HIV and other sexually transmitted infections, and its approval has helped accelerate the development of HIV treatment and prevention programs in the U.S. The combination of this drug and ZYB will help the company address the significant shortage of treatment options in HIV treatment.
Trial-grade darunavir (Lamivudine): The company is the only company that has been able to successfully use the darubigine (DAR) receptor in the body for the long-term treatment of chronic HIV infection.
Acetaminophen (Tylenol): This popular drug is used to help treat acute nausea and vomiting and the nausea associated with chemotherapy.
Pregnancy-related medications: Tylenos, the most common birth control pill in the world, is the leading birth control method in the US.
This includes both emergency contraception and birth control pills, which can be taken without a prescription.
Tylers are also the preferred method for emergency contraception for women who have had a pregnancy or who are at risk for becoming pregnant.
Nonprescription medications: There are approximately 50 million prescriptions filled annually for nonprescription drugs.
The combination of these medications, along with ZYBS, is what makes it the first drug company to be able to deliver the full range of its drugs and clinical trials at one location.
This means the company will be able focus on the more important areas, such as the drug development and manufacturing, as well as clinical trials.
As with other drug acquisitions, the price tag will vary based on the size of the transaction.
Turing will pay $1.4 billion for its intellectual-owned assets and $6 billion for clinical trial assets.